INT105884

From wiki-pain
Revision as of 02:17, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 19
Total Number 19
Disease Relevance 15.67
Pain Relevance 3.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Bcl2) aging (Bcl2) cell morphogenesis (Bcl2)
endoplasmic reticulum (Bcl2) intracellular (Bcl2) response to stress (Bcl2)
Anatomy Link Frequency
thymus 3
pore 1
centrocyte 1
Bcl2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Morphine 9 99.06 Very High Very High Very High
cva 24 95.40 Very High Very High Very High
Hippocampus 16 92.32 High High
depression 5 90.20 High High
Inflammatory response 6 88.72 High High
anesthesia 7 87.80 High High
Inflammation 77 86.16 High High
addiction 3 85.48 High High
medulla 19 85.16 High High
Bile 9 83.12 Quite High
Disease Link Frequency Relevance Heat
Death 102 99.56 Very High Very High Very High
Apoptosis 485 99.44 Very High Very High Very High
Chronic Lymphoid Leukemia 175 98.90 Very High Very High Very High
Lymphatic System Cancer 73 98.48 Very High Very High Very High
Cancer 91 98.44 Very High Very High Very High
Lactic Acidosis 1 97.14 Very High Very High Very High
Synovial Sarcoma 1 96.48 Very High Very High Very High
Hypothermia 138 96.08 Very High Very High Very High
Lung Cancer 3 95.76 Very High Very High Very High
Hemorrhage 60 95.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Group 1 had increased ratios of bcl-2/beta-actin, bax/beta-actin, and bax/bcl-2 mRNA at 1 h after CPB (bcl-2/beta-actin, 0.82 +/- 0.14 versus 0.63 +/- 0.07; P = 0.03; bax/beta-actin, 1.04 +/- 0.14 versus 0.56 +/- 0.03; P = 0.00; bax/bcl-2, 1.31 +/- 0.12 versus 0.84 +/- 0.09; P = 0.02; Group 1 versus Group 2, respectively).
bcl-2 Binding (ratios) of
1) Confidence 0.35 Published 2006 Journal Anesth. Analg. Section Abstract Doc Link 16551891 Disease Relevance 0.36 Pain Relevance 0.24
Group 1 had increased ratios of bcl-2/beta-actin, bax/beta-actin, and bax/bcl-2 mRNA at 1 h after CPB (bcl-2/beta-actin, 0.82 +/- 0.14 versus 0.63 +/- 0.07; P = 0.03; bax/beta-actin, 1.04 +/- 0.14 versus 0.56 +/- 0.03; P = 0.00; bax/bcl-2, 1.31 +/- 0.12 versus 0.84 +/- 0.09; P = 0.02; Group 1 versus Group 2, respectively).
bcl-2 Binding (ratios) of
2) Confidence 0.35 Published 2006 Journal Anesth. Analg. Section Abstract Doc Link 16551891 Disease Relevance 0.36 Pain Relevance 0.24
Overexpression of one or more of these antiapoptotic proteins, the most recognized of which is Bcl-2, essentially acts as a survival factor for cancer cells and is associated with resistance to chemotherapy in a number of hematologic cancers and solid tumors (Reed et al 1994; Klasa et al 2002; Reed 2006).
Bcl-2 Binding (recognized) of associated with cancer and solid tumor
3) Confidence 0.30 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 1.33 Pain Relevance 0.08
The phosphorothioate oligonucleotide oblimersen is particularly well designed for the treatment of patients with CLL, having been engineered to prevent translation of the Bcl-2 protein that is associated with both the pathogenesis of CLL and resistance to chemotherapy.
Bcl-2 Binding (associated) of associated with chronic lymphoid leukemia
4) Confidence 0.29 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 1.05 Pain Relevance 0
Formation of the RNA/antisense DNA duplex recruits RNase H, which degrades the RNA strand and releases the antisense DNA strand, allowing the drug to bind and cleave additional bcl-2RNA molecules, thus preventing translation of the Bcl-2 protein.
bcl-2RNA Binding (bind) of
5) Confidence 0.29 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 0.57 Pain Relevance 0
Data suggest that Bcl-2 negatively regulates the size or voltage potential of a mitochondrial-transmembrane pore by interacting with the pro-apoptotic protein Bax (Cheng et al 2001; Tsujimoto and Shimizu 2002).
Bcl-2 Binding (interacting) of in pore associated with apoptosis
6) Confidence 0.29 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376092 Disease Relevance 1.28 Pain Relevance 0.06
B, P-selectin, Bax, and Bcl-2 in thymus was negative
Bcl-2 Binding (negative) of in thymus
7) Confidence 0.22 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234334 Disease Relevance 0.54 Pain Relevance 0.18
B, P-selectin, Bax, Bcl-2, and Caspase-3 protein expression of thymus under light microscope,
Bcl-2 Binding (microscope) of in thymus
8) Confidence 0.22 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234334 Disease Relevance 0.31 Pain Relevance 0.20
B, P-selectin, Bax, Bcl-2, and Caspase-3 protein expression of thymus under light microscope,
Bcl-2 Binding (thymus) of in thymus
9) Confidence 0.22 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234334 Disease Relevance 0.25 Pain Relevance 0.20
Morphine increases Beclin 1 expression and reduces the interaction between Beclin 1 and Bcl-2, thus releasing Beclin 1 for its pro-autophagic activity.
Bcl-2 Binding (interaction) of associated with morphine
10) Confidence 0.19 Published 2010 Journal Autophagy Section Abstract Doc Link 20190558 Disease Relevance 0.50 Pain Relevance 0.86
G(2)-M arrest was associated with phosphorylation of Bcl2 (but not BAD, Bax, or Bcl-XL): both of these end points were abrogated by treatment with a calcium chelator.
Bcl2 Binding (associated) of
11) Confidence 0.17 Published 2002 Journal Cancer Res. Section Abstract Doc Link 12384529 Disease Relevance 0.80 Pain Relevance 0.12
If Bax homodimers predominate cell death will occur, but when Bcl-2 and Bax heterodimererization prevails cells can survive.
Bcl-2 Binding (heterodimererization) of associated with death
12) Confidence 0.16 Published 2006 Journal BMC Complement Altern Med Section Body Doc Link PMC1397864 Disease Relevance 0.94 Pain Relevance 0.17
Treatment with Cl was associated with greater Bcl-2 and attenuated Bax expression as compared to the control IR group.
Bcl-2 Binding (associated) of
13) Confidence 0.16 Published 2006 Journal BMC Complement Altern Med Section Body Doc Link PMC1397864 Disease Relevance 1.34 Pain Relevance 0.05
The centrocyte-like cells were immunohistochemically positive for CD20 and CD79a, and were negative for BCL2, CD3, CD5, and CD10; this was compatible with primary mucosa-associated lymphoid tissue (MALT) lymphoma.
BCL2 Binding (negative) of in centrocyte associated with lymphatic system cancer
14) Confidence 0.08 Published 2010 Journal Int Surg Section Abstract Doc Link 20480837 Disease Relevance 0.58 Pain Relevance 0.07
In a small animal model of lethal hemorrhage treated with profound hypothermia, our team has demonstrated decreased lactic acidosis and improved survival along with a significant decrease in apoptotic proteins, preserved phosphorylated Akt levels, and increased prosurvival intermediates such as Bcl-2 and ?
Bcl-2 Binding (intermediates) of associated with hypothermia, lactic acidosis, cva and apoptosis
15) Confidence 0.05 Published 2009 Journal Scand J Trauma Resusc Emerg Med Section Body Doc Link PMC2806855 Disease Relevance 1.88 Pain Relevance 0.24
Mechanistic events of how Mito-KATP exerts its protective effect has been unclear, but a recent study showed that activation of Mito-KATP by diazoxide increases the association of Bcl-2 with mitochondria, while prevents Bax translocation to mitochondria [74].


Bcl-2 Binding (association) of
16) Confidence 0.04 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647147 Disease Relevance 0.47 Pain Relevance 0
Immunohistochemical studies revealed reactivity for CD34, CD99 and Bcl-2, but no staining for desmin, inhibin, c-kit, EMA, CK, SMA, S-100 and CD31, confirming a diagnosis of SFT.
Bcl-2 Binding (reactivity) of associated with cancer
17) Confidence 0.02 Published 2005 Journal In Vivo Section Abstract Doc Link 15999548 Disease Relevance 1.19 Pain Relevance 0.07
Immunohistochemical testing was positive for CD45, CD20, CD10, and BCL-6, and negative for CD3, TdT, and BCL-2; which was consistent with Burkitt's lymphoma.
BCL-2 Binding (negative) of associated with lymphatic system cancer
18) Confidence 0.02 Published 2008 Journal Cases J Section Body Doc Link PMC2438318 Disease Relevance 1.02 Pain Relevance 0.08
Immunohistochemical testing was positive for CD45, CD20, CD10, and BCL-6, and negative for CD3, TdT, and BCL-2; which was consistent with Burkitt's lymphoma.
BCL-2 Binding (negative) of associated with lymphatic system cancer
19) Confidence 0.02 Published 2008 Journal Cases J Section Body Doc Link PMC2438318 Disease Relevance 0.89 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox